Clinical Outcome Demonstrates Material Benefits for Patients
Released
Released
Announcement PDF
ASX Announcement
28 March 2025
Outstanding Clinical Outcome Demonstrates Material Benefits for Patients
Using NervAlign® Nerve Cuff
Highlights:
• Recently presented study demonstrates statistically significant benefits for patient outcomes when using
the NervAlign® Nerve Cuff in peripheral nerve repair surgery.
• Patients undergoing peripheral nerve surgery that utilised the NervAlign® Nerve Cuff experienced a major
decrease in post-surgery pain measures compared to patients whose surgery did not utilise the Nerve Cuff.
•
Mean post-operative pain scores decreased from 7.1 to 0.4 with the Nerve Cuff, compared to a
reduction in scores from 7.1 to 3.3 without the Nerve Cuff.
•
Patients treated with the Nerve Cuff also reported higher satisfaction with their surgery compared
to those that did not receive the Nerve Cuff (93% of patients with the Nerve Cuff said they would
elect to have surgery again vs. 70% of patients without the Nerve Cuff).
• NervAlign® Nerve Cuff demonstrates clear benefits to patients’ post nerve repair, leading to better patient
outcomes.
ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”), a medical device company developing novel
peripheral nerve repair products, is pleased to announce the highly positive results from a recent nerve repair
comparative study. The results of the study show that patients benefit from the use of the NervAlign® Nerve Cuff
compared to those who do not have the Nerve Cuff incorporated in their treatment, reporting significantly lower
post-surgery measures of pain. Furthermore, as an indication of patient satisfaction post-surgery, patients who
were treated with the Nerve Cuff were more likely to indicate they would have their procedure again than those
that were not treated with the Nerve Cuff.
The study data has been presented this week at the American College of Foot and Ankle Surgeons (ACFAS 2025) Annual
Conference in Arizona, in a presentation titled: Efficacy of a Porcine Pericardium Nerve Wrap in Peripheral Nerve
Surgery. Namany et al. ACFAS 2025 (refer Abstract Ref ID Sci-743
https://www.acfas.org/admin/ACFAS/media/PDF/Abstract-Report-1.pdf )
on
page
372
-
Link:
Commenting on the study’s results and the improved patient outcomes resulting from use of the Nerve Cuff,
ReNerve CEO, Dr Julian Chick, stated: “These are very significant results for the development of ReNerve’s
products, as they highlight the utility of the NervAlign® Nerve Cuff in reducing patients’ pain following peripheral
nerve surgery. The results clearly demonstrate the patient benefits that follow from the proper repair and
regeneration of a nerve that is returned to normal function post-surgery. The NervAlign® Nerve Cuff facilitates the
patient's repair process is protected during the initial post-operative recovery and regeneration period. Thereafter,
because the Nerve Cuff is absorbed naturally after six months, there is no longer a lasting 'foreign body' at the site
of repair to create potential complications for the patient."
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
The NervAlign® Nerve Cuff
ReNerve’s NervAlign® Nerve Cuff is designed for the protection of repaired and regenerating nerves during the
healing process after peripheral nerve injuries or repair surgery. The product is unique as it protects the nerve
while healing, but is also naturally absorbed within six months, leaving only regenerated and repaired tissue in the
body. The medical properties of the NervAlign® Nerve Cuff mean that it is well suited for use in a wide range of
surgical procedures.
Study Design: Efficacy of a Porcine Pericardium Nerve Wrap in Peripheral Nerve Surgery1
The study examined the use of the NervAlign® Nerve Cuff in peripheral nerve repair surgeries and used two end
points – the first being an independent pain score assessment using the Visual Analogue Scale (VAS) methodology,
measured pre- and post-surgery; and the second being whether the patient would elect to have the procedure
again following the surgery and their recovery period.
• Study Size: 13 with Nerve Cuff; 10 without Nerve Cuff
• Gender: 21 Female, 2 Male
• Average Patient Age: 53 years old
• Follow-up: 2 - 36 months; Average follow-up = 9.25 months.
• Inclusion criteria: foot or ankle pain that could be improved with peripheral nerve surgery (PNS).
• Exclusion criteria: patients with previous history of PNS in the same extremity.
Results2
The study1 presented by Dr Adams demonstrates the significant benefits of using the NervAlign® Nerve Cuff in
peripheral nerve repair surgery. Patients who underwent surgery with the NervAlign® Nerve Cuff experienced a
significant (p=0.021) decrease in post-surgery pain compared to those who did not use the Nerve Cuff. These data
show that there is a clear benefit to patients when their neurectomies (repaired nerves) are protected for the
healing process using the NervAlign® Nerve Cuff. The use of post-operative pain scores as a clinical marker was
useful in this study as every case was for a foot and ankle surgery. These regions take considerable movement and
overall patient body weight compared to upper limbs and therefore nerve pain is correlated to the condition of
the nerve and related nerve damage and recovery.
1, 2 “Efficacy of a Porcine Pericardium Nerve Wrap in Peripheral Nerve Surgery” March 2025 Namany et al. ACFAS 2025
(https://imis.acfas.org/ACFAS2025/ACFAS2025/Abstracts.aspx?hkey=5209f2e8-69fc-4935-8823-799c8f5c2922) Abstract Ref ID Sci-743
2|Page
Clinical data
Figure 1. The comparison of pain scores between the two cohorts of patients
Independent Patient Pain Scores
Standard of Care
Standard
deviation
Protected with the
NervAlign® Nerve Cuff
Standard
deviation
Pre-surgery Pain Score
7.1
2.3
7.1
1.8
Post-surgery Pain Score
3.3
3.3
0.4
0.7
The pain score rating used in the study followed a standard pain score rating* such as:
•
0 = No pain.
•
1 = Pain is very mild, barely noticeable. Most of the time you don't think about it.
•
2 = Minor pain. It's annoying. You may have sharp pain now and then.
•
3 = Noticeable pain. It may distract you, but you can get used to it.
•
4 = Moderate pain. If you are involved in an activity, you're able to ignore the pain for a while. But it is
still distracting.
•
5 = Moderately strong pain. You can't ignore it for more than a few minutes. But with effort you can still
work or do some social activities.
3|Page
•
6 = Moderately stronger pain. You avoid some of your normal daily activities. You have trouble
concentrating.
•
7 = Strong pain. It keeps you from doing normal activities.
•
8 = Very strong pain. It's hard to do anything at all.
•
9 = Pain that is very hard to bear. You can't carry on a conversation.
•
10 = Worst pain possible.
* Taken from the Kaiser Permanente pain score - https://healthy.kaiserpermanente.org/health-wellness/health-encyclopedia/he.learning-aboutthe-0-to-10-pain-scale.abs0043
Percentage of patients that would elect to have their surgery again
Would you elect to have surgery again
Yes
No
Standard of Care
70%
30%
Protected with NervAlign® Nerve Cuff
93%
7%
Figure 2. Patient Implants of the Ner vAlign ® Nerve Cuff from the Study.
Conclusion
The results of this study illustrate the benefits to patient outcomes from the use of the NervAlign® Nerve Cuff as a
protection for a recently repaired nerve after surgery.
This announcement has been approved for release by the Company’s Board of Directors.
4|Page
ENDS -
For further information and enquiries, please contact:
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Jane Morgan
Investor & Media Relations
Jane Morgan Management
+61 (0) 405 555 618
info@janemorganmanagement.com.au
About ReNerve Limited
ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration
solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering
products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap
in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been
developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable
products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation
program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff™.
5|Page
Share your feedback
Discover